Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Amicus Therapeutics: Moving Towards Consistent Profitability [Seeking Alpha]